AD

Award Number: DAMD17-99-1-9170

TITLE: Roles of BRCA2 Gene in Homologous Recombination and Genomic Stability

PRINCIPAL INVESTIGATOR: David J. Chen, Ph.D.

CONTRACTING ORGANIZATION: University of California

Berkeley, California 94720

REPORT DATE: September 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching and atas sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

Wallagement and Budget, 1 aperwork recodesort 10je	·			
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE September 2001	3. REPORT TYPE AND Annual (1 Sep		
4. TITLE AND SUBTITLE			5. FUNDING N	UMBERS
Roles of BRCA2 Gene in H	iomologous Recombinati	on and	DAMD17-99-	-1-9170
Genomic Stability				
6. AUTHOR(S)				
David J. Chen, Ph.D.				
7. PERFORMING ORGANIZATION NAM	ME(S) AND ADDRESS(ES)		8. PERFORMIN	G ORGANIZATION
University of California			REPORT NU	MBER
Berkeley, California 94	720			
E-Mail: DJChen@lbl.gov				
E-Wall. DJChen@101.gov				
9. SPONSORING / MONITORING AGE	NCY NAME(S) AND ADDRESS(ES	5)	1	NG / MONITORING EPORT NUMBER
U.S. Army Medical Research and M	Materiel Command		AGENCY	EFORT NOWBER
Fort Detrick, Maryland 21702-5012				
11. SUPPLEMENTARY NOTES				
Report contains color				
40 DIOTRIBUTION / AVAILABILITY	TA TERFEIT			12L DISTRIBUTION CODE
12a. DISTRIBUTION / AVAILABILITY S Approved for Public Rele		imited		12b. DISTRIBUTION CODE
	,			
13. ABSTRACT (Maximum 200 Words				
The <i>Brca2</i> tumor supressor gene is				
recombinational repair. Brca2 is pr				
11 and 27 of Brca2 code for domai distinct interaction domain. Deletic				
phenotype is seen in mice with dele	etions that preserve some but no	ot all of the BRC moti	fs. These mice	can survive nast weaning, but
are runted, infertile, and die very yo	oung from cancer. Cells derive	d from such mice are h	vpersensitive to	some genotoxic agents and
exhibit chromosomal instability. H	lere we present analysis of mice	and cells with a deletion	on of the single	Rad51-interacting region
encoded by exon 27 (all the BRC n	notifs are preserved). This muta	ation is called brca2lex1	. Mice homozy	gous for brca2lex exhibit a
shorter life span compared to contr	ol littermates, possibly due to a	n early onset of cancer	and sepsis. No	other phenotype was observed
in these animals; therefore, the brea				
the BRC motifs. However, at the c	ellular level, the brca2iexi mutat	tion causes reduced via	bility, extreme s	sensitivity to the DNA

14. SUBJECT TERMS			15. NUMBER OF PAGES
Breast Cancer			11
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

interstrand cross-linking agent mitomycin C, and gross chromosomal instability, much like the more severe truncations..

Table of Contents

over	. 1
F 298	2
able of Contents	3
itroduction	4
ody4	-7
onclusions	7
ey Research Accomplishments	7
eportable Outcomes	8
eferences	9
ppendices10-1	1

Introduction

The BRCA2 protein has been shown to physically interact with the DNA repair and homologous recombination protein RAD51, both in vitro and in vivo (Chen et al., 1998; Katagiri et al., 1998; Marmorstein et al., 1998; Mizuta et al., 1997; Sharan et al., 1997; Wong et al., 1997) suggesting that BRCA2 participates in a recombination complex during cell division and DNA repair processes. Shortly after exposure of normal cells to ionizing radiation, RAD51 protein relocalizes to form discrete nuclear foci, which have been proposed to represent the assembly of multiprotein recombinational repair complexes at sites of DNA damage (Chen et al., 1998a; Chen et al., 1999; Haaf et al., 1995). In Capan-1 human cells, which lack an intact BRCA2 gene, formation of RAD51 foci is severely impaired (Yuan et al., 1999). The latter cells are also hypersensitive to ionizing radiation and to drugs that cause DNA double-strand breaks, and show reduced repair of DNA double-strand breaks after radiation exposure (Abbott et al., 1998). If loss of the interactions between BRCA2 and RAD51 results in reduced capacity for homologous repair of DNA double-strand breaks or homology-dependent repair of other lesions during DNA replication, this may in turn contribute to genomic instability, and result in the eventual mutation of genes required for control of cell growth and division.

Morimatus has reported the generation of embryonal stem (ES) cells in which both alleles of the *BRCA2* gene have been truncated by gene targeting, using two different targeting vectors (Morimatsu et al., 1998). Both truncations delete exon 27, which encodes the extreme carboxy-terminal RAD51-interaction domain of the BRCA2 protein. The two targeted alleles have been designated *BRCA2lex1* and *BRCA2lex1/lex2* ES cells are hypersensitive to ionizing radiation but not to ultraviolet radiation. The *BRCA2lex1/lex2* ES cells were used to generate primary mouse embryonal fibroblasts (MEF). Primary *BRCA2lex1/lex2* MEF cells show an impaired growth rate and reduced cloning efficiency as compared to primary *BRCA2+/+* MEF, and undergo premature replicative senescence as determined by colony size distribution and serial passage (3T3-equivalent) analysis.

We have reported the characterization of these cells for sensitivity to mitomycin C, which produces DNA interstrand crosslinks; a type of damage thought to require repair through homologous recombination. Here we further characterize the phenotype of mice and mouse embryonic fibroblasts (MEF) with a deletion of exon 27 (designated $brca2^{lexl}$). Compared to control mice, the $brca2^{lexl}$ mice exhibit a decreased life span that may be partially due to an early onset of cancer and sepsis. The $brca2^{lexl}$ allele exhibits a normal Mendelian pattern of inheritance, indicating no loss of viability in homozygous embryos. In addition, $brca2^{lexl}$ mice are of normal size and fertile; unlike mice with the larger COOH-terminal truncations that retain some of the BRC motifs. Thus, the $brca2^{lexl}$ mutation is very mild, and suggests only a modest impairment of Brca2 activity. However, even though $brca2^{lexl}$ mice exhibit a mild phenotype, MEF bearing this mutation exhibit impaired growth, gross chromosomal instability and severe hypersensitivity to the interstrand crosslinking agent mitomycin C.

Body

1) Life Span of $brca2^{lex1/lex1}$ and Control Mice. We compared the life span of $52 \ brca2^{lex1/lex1}$ mice to $35 \ control$ mice (Figure 1b). Included in the control cohort are $Brca2^{+/4}$, $Brca2^{+/lex1}$, and $Brca2^{+/lex2}$ mice. Heterozygote mice were included because there is little phenotypic abnormality in these mice. Mortality came sooner for the $brca2^{lex1/lex1}$ mice compared to control mice. The onset of mortality is about the same for $brca2^{lex1/lex1}$ and control mice; 50 - 60 weeks. However, the life span curves began to diverge at about 70 weeks and were significantly different by 93 weeks (p < 0.1). This divergence progressed until the

study was terminated, when the youngest mice were 108 weeks, (p < 0.01). About 50% of the $brca2^{lex1/lex1}$ mice die by 89 - 90 weeks while 50% of the control mice die by 104 - 108 weeks.




Figure 1. The $brca2^{lexl}$ and the $brca2^{lex2}$ mutations in mice. **A.** Day E10.5 embryos harvested from a $brca2^{+llex2}$ female mated with a $brca2^{lex1/lex2}$ male. The larger embryo is $brca2^{lex1/lex2}$ compound heterozygote and appears morphologically normal. The much smaller (partially resorbed) embryo indicated by the arrow at left is a $brca2^{lex2/lex2}$ homozygote. **B.** Survival curve of $brca2^{lex1/lex1}$ (blue diamonds) and control (red squares) mice. The percent alive are shown.

2) Pathology of brca2^{lex1/lex1} and Control Mice. Moribund and recently dead mice were observed by necropsy. Additionally, all remaining mice were sacrificed at the point when the survival curve reached 49% for the control population. Abnormal tissues and potential tumors were examined by histopathology, as summarized in Table 1. Both brca2^{lext/lext} and control mice exhibit a wide range of cancers. However, onsets of cancer and sepsis (the latter indicated by reactive immune responses) were somewhat earlier in the brca2^{lex1/lex1} mice. From weeks 67 to 104, 11 brca2^{lex1/lex1} mice (~20% of the population) developed lifethreatening pathology (either cancer or sepsis) while at week 104 the first control mouse exhibited lifethreatening disease. The average age of onset for frank neoplasias, considering only tumors that arose through 108 weeks, was 81 weeks for the $brca2^{lexI/lexI}$ mice as compared to 106 weeks for controls (p < .005). The cumulative incidence of cancers and reactive immune responses was significantly higher in the brca2^{lex1/lex1} cohort compared to the control cohort by week 87 and continued to diverge through 108 weeks (p values from <.05 to .01). Since many of the $brca2^{lex1/lex1}$ mice were generated after the control mice, not as many brca2^{lexI/lexI} mice as controls were observed at ages older than 110 weeks (9 compared to 16) or older than 120 weeks (1 compared to 7). For this reason, the frequency of late onset disease is not known for the brca2^{lex1/lex1} mice and cannot be compared to control mice. Moreover, the differences seen through 108 weeks, while statistically significant, should be interpreted with caution given the small numbers of animals involved. Nonetheless, the shortened life span observed in the brca2^{lex1/lex1} cohort appears to be due, at least in part, to early onsets of cancer and sepsis.

mouse	genotype	week	histopathology
284H	lex1/lex1	67	messenteric abscess
246H	lex1/lex1	77	colonic adenocarcinoma
107H	lex1/lex1	79	hepatocellular carcinoma
109H	lex1/lex1	82	fatty liver with focal inflamation
103H	lex1/lex1	86	granulamatous inflamation in spleen
264H	lex1/lex1	87	malignant lymphoma
164H	lex1/lex1	90	reactive lymphoid hyperplasia in spleen
094H	lex1/lex1	96	granulamatousinflamation in lymph nodes and skin
281H	lex1/lex1	98	massive lymphoid hyperplasia in lymph nodes, possibly lymphoma
267H	lex1/lex1	101	reactive lymphoid hyperplasia in lymph nodes, spleen, liver, kidney
050H	lex1/lex1	104	hepatocellular carcinoma
256H	lex1/lex1	114	osteosarcoma
022N	+/lex2	104	hepatocellular carcinoma
028H	+/+	108	leimyosarcoma
051H	+/lex1	116	hemangiosarcoma
053H	+/lex1	116	hepatocellular carcinoma
058H	+/lex1	119	malignant lymphoma
049H	+/lex1	129	hepatocellular carcinoma

Table 1. Pathology of *brca2*^{lexI/lexI} and Control Mice.

3) To assess the relative effects of DNA damage on chromosomal integrity in wild type and $brca2^{lex1/lex2}$ immortalized MEF. Metaphase spreads were prepared 24 hours after exposure to 6 Gy of γ -radiation or to mitomycin C at 5 x 10^{-8} M. After γ -irradiation, there were significantly increased numbers of chromatid- and chromosome-type abnormalities in $brca2^{lex1/lex2}$ MEF relative to non-irradiated controls, but this was also true for wild type MEF (See Appendix – Table2). The numbers of chromatid and chromosome aberrations present in $brca2^{lex1/lex2}$ MEF after irradiation were only slightly higher than in wild type MEF. This is consistent with the modest difference between $brca2^{lex1/lex2}$ and wild type cells in viability after γ -irradiation, and indicates that $brca2^{lex1/lex2}$ cells have nearly the proficiency of wild-type cells in repairing the DNA damage induced by ionizing radiation. Mitomycin C at 5 x 10^{-8} M produced no significant increase in chromatid- or chromosome-type abnormalities in wild type MEF (Table 2), suggesting that cells expressing normal Brca2 were able to repair most of the interstrand crosslinks created. In $brca2^{lex1/lex2}$ MEF, however, the frequency of chromatid-type aberrations increased more than two-fold after mitomycin C exposure (Table 2. p < 0.001).

We wished to determine whether the chromosomal instability seen in immortalized $brca2^{lex1/lex2}$ MEF arose during the process of immortalization, or already existed in primary cells prior to senescent crisis. We therefore examined early-passage primary MEF for chromosomal abnormality. Two populations of $brca2^{lex1/lex2}$ MEF and three populations of wild type MEF (Morimatsu et~al., 1998) that had been frozen at the first passage after dissociation from embryos (passage 1) were thawed and passaged, with metaphase spreads prepared at each passage. Passage 1 wild-type MEF grew vigorously after thaw and showed no appreciable slowing of growth over at least ten passages afterward (data not shown). However, the $brca2^{lex1/lex2}$ MEF senesced prematurely in culture, as reported previously (Morimatsu et~al., 1998). and could not be expanded beyond the fourth passage. For one of the two primary $brca2^{lex1/lex2}$ MEF populations examined (281.1), sufficient numbers of metaphase cells for scoring were recovered only at the second and third passages. Scoring of early passage primary MEF for chromosomal aberrations is

summarized in Appendix – Table3. Compared to wild type primary MEF, the $brca2^{lexIMex2}$ primary MEF had sharply elevated numbers of chromatid and chromosome aberrations, including gaps, breaks, deletions and exchanges. The $brca2^{lexIMex2}$ MEF had higher numbers of chromosomal aberrations even at passage 2, and accumulated further aberrations more rapidly than wild type MEF. By the third passage, approximately half the metaphase cells in $brca2^{lexIMex2}$ populations had one or more visible chromosome abnormalities. These results confirm that the chromosomal instability seen in immortalized $brca2^{lexIMex2}$ MEF results directly from the $brca2^{lexIMex2}$ mutation, and not from additional mutations acquired during or after immortalization.

Conclusion and Summary

The results obtained here confirm that the extreme COOH-terminal region encoded by exon 27, though not essential to viability, is important for the function of Brca2 at the cellular level. It remains a possibility that the phenotypic effects associated with deletion of exon 27 result from something other than altered interactions with Rad51. In humans, the Brca2 protein is dependent upon nuclear localization signals encoded within exon 27 for transport into the nucleus (Spain *et al.*, 1999). However, this is evidently not the case for mouse Brca2, since the protein encoded by the brca2^{lex1} allele reaches the nucleus (Moynahan *et al.*, 2001). Thus, in mouse, interaction with Rad51 is the only function so far demonstrated for the region encoded by exon 27. This raises the interesting question of why the Brca2 protein should require multiple Rad51 interaction domains (the BRC repeats as well as the region encoded by exon 27) to be fully functional.

Although the cellular phenotypes of the brca2^{lex1} truncation and the longer COOH-terminal Brca2 deletions are similar, the mouse phenotypes are very different. Mice homozygous for either of the long COOH-terminal deletions exhibit partial pre-adulthood lethality, infertility, runted growth and high incidence of thymic lymphoma before six months of age (Connor et al., 1997; Patel et al., 1998; Friedman et al., 1998). However, mice that are homozygous for the brca2^{lex1} truncation appear relatively normal. They grow, reach adulthood, and are fertile much like their control littermates. Nearly all the mice survive beyond one year of age, yet their life span is significantly shorter than control mice, possibly due to early onsets of cancer and sepsis. That the larger COOH-terminal deletions have severely deleterious phenotypes is perhaps unsurprising, given that they eliminate more than a third (Connor et al., 1997), or more than half (Patel et al., 1998) of the Brca2 protein. The large COOH-terminal regions lost in these mutations are likely to contain additional domains with important functions, and so the resulting phenotypes cannot be ascribed with certainty to the loss of Rad51-interacting regions alone. The brca2^{lex1} allele deletes less than 6% of the protein and leaves all eight of the BRC repeats, as well as the intervening region coded by exons 12-26 intact. Moreover, the truncated Brca2 protein encoded by the $brca2^{lext}$ allele retains the capacity to bind Rad51, presumably via the BRC repeats (Moynahan et al., 2001). Nonetheless, the $brca2^{lext}$ allele produces a qualitatively similar cellular phenotype as the larger deletions. Thus, while the more severe phenotypes seen in mice with longer COOH-terminal deletions may be the result of more severely impaired HRR, it is also possible that they reflect loss of functions unrelated to Rad51. Due to this possibility, the brca2^{lex1/lex1} mice are an ideal genetic background to evaluate mutations in other genes suspected to functionally interact with Brca2. They may also have utility in testing putative clastogens or carcinogens, since they are predisposed to genetic instability, but exhibit such a mild phenotype.

Key Research Accomplishments

• The BRCA2^{lex2} allele is embryonic lethal when homozygous

- Mice homozygous for either of the long COOH-terminal deletions exhibit partial pre-adulthood lethality, infertility, runted growth and high incidence of thymic lymphoma before six months of age
- BRCA2lex1/lex2 MEF exhibit chromosomal instability

Reportable Outcomes

- We have generated mouse immortalized BRCA2lex1/lex2 MEF
- A postdoctoral fellow, Dr. Mark Breenman was hired for this study
- A Scientist, Dr. Yi-Ching Lio is hired to continue this research

References

- Abbott, D.W., Freeman, M.L. & Holt, J.T. (1998). J Natl Cancer Inst, 90, 978-85.
- Chen, J.J., Silver, D., Cantor, S., Livingston, D.M. & Scully, R. (1999). Cancer Res, 59, 1752s-1756s.
- Chen, P.L., Chen, C.F., Chen, Y., Xiao, J., Sharp, Z.D. & Lee, W.H. (1998b). *Proc Natl Acad Sci U S A*, 95, 5287-92.
- Connor, F., Bertwistle, D., Mee, P.J., Ross, G.M., Swift, S., Grigorieva, E., Tybulewicz, V.L. & Ashworth, A. (1997). *Nat Genet*, 17, 423-30.
- Cui, X., Brenneman, M., Meyne, J., Oshimura, M., Goodwin, E.H. & Chen, D.J. (1999). *Mutat Res*, 434, 75-88.
- Friedman, L.S., Thistlethwaite, F.C., Patel, K.J., Yu, V.P., Lee, H., Venkitaraman, A.R., Abel, K.J., Carlton, M.B., Hunter, S.M., Colledge, W.H., Evans, M.J. & Ponder, B.A. (1998). *Cancer Res*, 58, 1338-43.
- Haaf, T., Golub, E.I., Reddy, G., Radding, C.M. & Ward, D.C. (1995). *Proc Natl Acad Sci U S A*, 92, 2298-302.
- Katagiri, T., Saito, H., Shinohara, A., Ogawa, H., Kamada, N., Nakamura, Y. & Miki, Y. (1998). Genes Chromosomes Cancer, 21, 217-22.
- Marmorstein, L.Y., Ouchi, T. & Aaronson, S.A. (1998). Proc Natl Acad Sci USA, 95, 13869-74.
- Mizuta, R., LaSalle, J.M., Cheng, H.L., Shinohara, A., Ogawa, H., Copeland, N., Jenkins, N.A., Lalande, M. & Alt, F.W. (1997). *Proc Natl Acad Sci U S A*, 94, 6927-32.
- Morimatsu, M., Donoho, G. & Hasty, P. (1998). Cancer Research, 58, 000-000.
- Moynahan, M.E., Chiu, J.W., Koller, B.H. & Jasin, M. (1999). Mol Cell, 4, 511-8.
- Moynahan, M.E., Pierce, A.J., & Jasin, M. (2001) Mol Cell, 7, 263-272
- Patel KJ, Y.V., Lee HS, Corcoran A, Thistletwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BAJ, Venkitaraman AR. (1998). *Molecular Cell*, 1(3), 347-357.
- Sharan, S.K., Morimatsu, M., Albrecht, U., Lim, D.S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P. & Bradley, A. (1997). *Nature*, 386, 804-10.
- Spain, B.H., Larson, C.J., Shihabuddin, L.S., Gage, F.H., and Verma, I.M., (1999) *Proc Natl Acad Sci U.S.A.* 96, 13920-5
- Wong, A.K.C., Pero, R., Ormonde, P.A., Tavtigian, S.V. & Bartel, P.L. (1997). *J Biol Chem*, 272, 31941-
- Yuan, S.S., Lee, S.Y., Chen, G., Song, M., Tomlinson, G.E. & Lee, E.Y. (1999). Cancer Res, 59, 3547-51.

Appendix:

- **Table 2.** Spontaneous and damage-induced chromosomal aberrations in immortalized wild type and brca2lex1/lex2 MEF cells.
- **Table 3.** Spontaneous chromosomal aberrations in early-passage wild type and Brca2^{lex1/lex2} primary MEF cells.

Table 2. Spontaneous and damage-induced chromosomal aberrations in immortalized wild type and brca2lex1/lex2 MEF cells.

MEF cells	Metaphases	Percent	Mean	Chr	Chromatid aberrations ¹	erration	181	Chron	Chromosome aberrations ²	aberratic	ns ²
		metaphases ³	per metaphase ³	gaps	gaps breaks other total ³	other 1	otal ³	int.del.	int.del. ter.del. other total	other	total
Wild type											
No treatment	30	20	0.800	Ŋ	6	0	7	6	ო	•	13
γ-irradiation	30	100	4.33	10	25	59	54	65	Ŋ	2	77
Mitomycin C	30	09	0.844	0	ω	9	4	∞	ß	0	13
brca2lex1/lex2			-								
No treatment	30	26	3.27	7	24	17	41	47	10	0	22
y-irradiation	30	100	5.07	17	35	24	59	75	0	18	63
Mitomycin C	30	66	4.60	13	99	30	96	27	4	-	42

1. "gaps" defined as discontinuities smaller than the width of the chromatid; "other" comprising isochromatid deletions and exchanges.
2. interstitial deletions; terminal deletions (including breaks); and other (including dicentric and ring chromosomes).
3. calculated without chromatid gaps.

Table 3. Spontaneous chromosomal aberrations in early-passage wild type and Brca2lex1/lex2 primary MEF cells.

MEF	Passage	Metaphases analyzed	Percent aberrant metaphases ³	Mean aberrations per Metaphase ³	Chron gaps b	natid ab	Chromatid aberrations ¹ ips breaks other total ³	s¹ otal³	Chron int.del.	Chromosome aberrations ² int.del. ter.del. other tot	berrations ² other tota	nns² total
Wil	Wild type											
129.5	P2 P3 P4	20 20 20	o 0 0	0.06 0.06 0.10	7 13 10		000		000	0 - 0	0 + 0	0 0 4
129.7	P2 P4	50 50 50	4 8 1	0.06 0.12 0.24	4 - 0	o - o	0 - 0	02 LD	000	220	000	047
129.9	P2 P3	50 50 50	8 26	0.04 0.08 0.28	0 + 7	0 0 0	000	0 7 50	000	0 0 ro	00-	0 N N
Brca'	Brca2lex1/lex2											
283.2	P P 3	50 50 42	24 58 48	0.40 2.22 1.02	22 14 22	11 50 18	0 0 4	13 56 22	23 0	7 32 27	000	7 55 29
281.1	P2 B3	50	52 62	0.76	5	23 35	2 0	23	വ വ	10	0 0	15 24

"gaps" defined as discontinuities smaller than the width of the chromatid; "other" comprising isochromatid deletions and exchanges.
 interstitial deletions; terminal deletions (including breaks); and other (including dicentric and ring chromosomes).
 calculated without chromatid gaps.